<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636311</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2006-005</org_study_id>
    <secondary_id>EUDRACT 2007-004883-29</secondary_id>
    <nct_id>NCT00636311</nct_id>
  </id_info>
  <brief_title>A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma</brief_title>
  <official_title>IGEV +/- Bortezomib (Velcade) as Induction Before High Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma After First Line Treatment: a Randomized Phase II Trial. On Behalf of Intergruppo Italiano Linfomi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the addition of Bortezomib (Velcade) to IGEV
      combination (Ifosfamide, Gemcitabine and Vinorelbine) in patients with relapsed/refractory
      Hodgkin's lymphoma increases the rate of complete remission (PET negativity) at
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET negativity rate obtained with IGEV or B-IGEV will be compared</measure>
    <time_frame>PET negativity after 4 courses of induction (IGEV or B-IGEV)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-IGEV (Bortezomib + IGEV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide, Gemcitabine, Vinorelbine</intervention_name>
    <description>Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib + IGEV</intervention_name>
    <description>Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Hodgkin's lymphoma failing or relapsing after first-line chemotherapy
             (MOPP/AVBD , MOPP/EBV/CAD and analogs are considered one line)

          -  Age &gt;18 and &lt;65 years

          -  Signed informed consent

          -  If female, patient is either postmenopausal or surgically sterilized or willing to use
             an acceptable method of birth control

          -  If male, patient agrees to use an acceptable barrier method for contraception

          -  ECOG performance status &lt;2

          -  Platelet count &gt;100.000/mmc

          -  Hemoglobin &gt;7.5 g/dL

          -  Absolute neutrophil count (ANC) &gt;1.500/mmc

          -  Serum calcium &lt;3.5 mmol/L (&lt;14 mg/dL)

          -  AST/ALT: &lt;2.5 x the ULN

          -  Total bilirubin: &lt;1.5 x the ULN

        Exclusion Criteria:

          -  Previous treatment with velcade

          -  Nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks before enrollment

          -  Immunotherapy or antibody therapy within 4 weeks before enrollment

          -  Experimental drug or medical device within 4 weeks before start of treatment

          -  Major surgery within 4 weeks before enrollment

          -  History of allergic reaction attributable to compounds containing boron or mannitol or
             any of the drugs in the IGEV regimen

          -  Peripheral neuropathy of NCI CTCAE Grade 2 or higher

          -  Myocardial infarction within 6 months of enrollment or NYHA Class III or IV heart
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities

          -  History of clinically relevant liver or renal insufficiency; significant cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,
             hematologic, psychiatric, or metabolic disturbances including diabetes mellitus

          -  Need for therapy with concomitant CYP 3A4 inhibitors or inducers

          -  HIV-positive, if known

          -  Hepatitis B surface antigen-positive or active hepatitis C infection, if known

          -  Active systemic infection requiring treatment

          -  If female, pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007 Jan;92(1):35-41.</citation>
    <PMID>17229633</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Armando Santoro, MD</name_title>
    <organization>Istituto Clinico Humanitas</organization>
  </responsible_party>
  <keyword>Hodgkin disease</keyword>
  <keyword>Salvage therapy</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

